A non-inferiority trial is a type of clinical study designed to demonstrate that a new treatment is not unacceptably less effective than an existing standard treatment. The primary objective is to show that the new intervention is at least as effective as the current standard of care, within a pre-specified margin of difference.
These trials are often used when the new treatment offers other advantages, such as fewer side effects, lower cost, or easier administration. Non-inferiority trials require careful design, including the selection of an appropriate non-inferiority margin and a suitable active comparator.
Non-inferiority trials are crucial in clinical research as they allow for the evaluation of new treatments that may offer advantages beyond efficacy alone. These trials are particularly valuable when it is unethical or impractical to use a placebo control, especially in cases where effective treatments already exist.
Understanding non-inferiority trials is essential for researchers, clinicians, and regulatory bodies involved in drug development and approval processes. This knowledge enables the appropriate design, conduct, and interpretation of studies that aim to introduce new therapeutic options with potential benefits such as improved safety profiles, reduced costs, or enhanced patient compliance.
Axcellant, a specialist global contract research organization (CRO), has been appointed by Switzerland-based Santersus AG to support the execution of…
Axcellant will participate in the Annual Congress of the European Association of Nuclear Medicine (EANM 2026), taking place from 17…
3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…
Copyright @ 2026 Axcellant|Privacy Policy|Cookie Policy|